Literature DB >> 2527239

Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations.

K Pollow1, R Kreienberg, N Di Pietro.   

Abstract

Two micronized oral formulations of medroxyprogesterone acetate (MPA) (Farlutal and Clinovir) were compared in order to evaluate their relative bioavailability. Sixteen female patients with metastatic breast cancer were entered in a randomized cross-over study on 500-mg MPA tablets repeatedly administered (twice daily for 20 days). At the steady state, similar mean +/- SD serum levels of MPA were obtained (131 +/- 44 ng/ml for Farlutal and 136 +/- 45 ng/ml for Clinovir) and the two formulations proved to be bioequivalent (confidence interval at a significance level of 0.95 = 93%-107%).

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2527239     DOI： 10.1007/bf00400970

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  9 in total

1.  Symmetrical confidence intervals for bioequivalence trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.

Authors:  F Pannuti; A Martoni; E Pollutri; P Camera; F Losinno; H Giusti
Journal:  Panminerva Med       Date:  1976 Mar-Apr       Impact factor: 5.197

3.  Measurement of medroxyprogesterone acetate (Provera ) by radioimmunoassay.

Authors:  J C Cornette; K T Kirton; G W Duncan
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

4.  Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; W J Sluiter; H Doorenbos
Journal:  Cancer Treat Rep       Date:  1985-09

5.  Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.

Authors:  L D Dikkeschei; H van Veelen; G T Nagel; P H Willemse; B G Wolthers
Journal:  J Chromatogr       Date:  1985-11-29

6.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.

Authors:  A D Stockdale; D Chapman; G P Mould; A Y Rostom
Journal:  Cancer Treat Rep       Date:  1987-09

8.  Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.

Authors:  V Tamassia; A Battaglia; F Ganzina; A M Isetta; G Sacchetti; F Cavalli; A Goldhirsch; K Brunner; G Bernardo; G Robustelli della Cuna
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation.

Authors:  E D Johansson; P B Johansen; S N Rasmussen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-05
  9 in total
  1 in total

Review 1.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.